Updated project metadata. Despite strong evidence of a significant role of MAPK signaling in chronic lymphocytic leukemia (CLL), phosphatase development and progression, this pathway is up to date not targeted in CLL therapy and available BRAF and MEK inhibitors are not efficient in reducing tumor progression. In this study, we evaluated the effects of targeted hyperactivation of the MAPK signaling pathway in CLL.